tiprankstipranks
Soleno Therapeutics Inc (SLNO)
NASDAQ:SLNO

Soleno Therapeutics (SLNO) Income Statement

611 Followers

Soleno Therapeutics Income Statement

Last quarter (Q3 2023), Soleno Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Soleno Therapeutics's net income was $-8.82M. See Soleno Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
---$ 0.00$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 21.86M$ 24.40M$ 31.53M$ 31.95M$ 23.20M$ 13.73M
Operating Income
$ -32.46M$ -24.40M$ -31.53M$ -31.95M$ -23.20M$ -13.73M
Net Non Operating Interest Income Expense
---$ 13.00K$ 154.00K$ 104.00K
Other Income Expense
$ 94.00K$ -330.00K$ -618.00K$ 7.30M$ -7.73M$ 1.79M
Pretax Income
$ -30.51M$ -25.49M$ -30.91M$ -24.64M$ -30.77M$ -11.84M
Tax Provision
$ 527.00K$ -527.00K$ 2.34M--$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -31.14M$ -25.49M$ -30.91M$ -24.64M$ -30.77M$ -13.34M
Basic EPS
$ -4.69$ -2.87-$ -0.39$ -0.90$ -0.64
Diluted EPS
$ -4.62$ -2.87$ -5.85$ -0.39$ -0.90$ -0.64
Basic Average Shares
$ 39.70M$ 8.40M$ 5.32M$ 62.62M$ 34.14M$ 20.98M
Diluted Average Shares
$ 39.70M$ 8.40M$ 5.32M$ 62.62M$ 34.14M$ 20.98M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 21.86M$ 24.40M$ 31.53M$ 31.95M$ 23.20M$ 13.73M
Net Income From Continuing And Discontinued Operation
$ -33.22M$ -24.10M$ -30.91M$ -24.64M$ -30.77M$ -13.34M
Normalized Income
$ -13.17M$ -26.02M-$ -31.94M$ -23.52M$ -13.79M
Interest Expense
------
EBIT
$ -30.51M$ -25.49M$ -30.91M$ -31.95M$ -23.20M$ -13.73M
EBITDA
$ -21.19M$ -23.53M$ -28.95M$ -30.00M$ -21.24M$ -11.77M
Currency in USD

Soleno Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis